Prion peptide-mediated cellular prion protein overexpression and neuronal cell death can be blocked by aspirin treatment

International Journal of Molecular Medicine

Volumn 27, Issue 5, 2011, Pages 689-693

  Jeong, Jae Kyo ^a   Moon, Myung Hee ^a   Seol, Jae Won ^a   Seo, Jae Suk ^a   Lee, You Jin ^a   Park, Sang Youel ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Aspirin; ERK1 2 phosphorylation; Neuronal cell death; Oxidative stress; Prion peptide (106 126)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLSALICYLIC ACID; CASPASE 3; CRYSTAL VIOLET; DNA; MITOGEN ACTIVATED PROTEIN KINASE; PRION PROTEIN; PROTEIN BCL 2; PROTEIN P53; SYNAPTOPHYSIN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NERVE CELL; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASPIRIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRIONS; PRPC PROTEINS; SIGNAL TRANSDUCTION;

EID: 79952903522     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.626     Document Type: Article

References (28)

1. Kovacs GG and Budka H: Prion diseases: from protein to cell pathology. Am J Pathol 172: 555-565, 2008. (Pubitemid 351354529)
2. Laurent M and Johannin G: Molecular clues to pathogenesis in prion diseases. Histol Histopathol 12: 583-594, 1997. (Pubitemid 27240328)
3. Kretzschmar HA: Molecular pathogenesis of prion diseases. Eur Arch Psychiatry Clin Neurosci 249 (Suppl. 3): 56-63, 1999.
4. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S and Collinge J: Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874, 2003. (Pubitemid 37339628)
5. Manson JC, Clarke AR, McBride PA, McConnell I and Hope J: PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3: 331-340, 1994.
6. Bueler H, Aguzzi A, Sailer A, et al: Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347, 1993. (Pubitemid 23201147)
7. Pietri M, Caprini A, Mouillet-Richard S, et al: Overstimulation of PrPC signaling pathways by prion peptide 106-126 causes oxidative injury of bioaminergic neuronal cells. J Biol Chem 281: 28470-28479, 2006. (Pubitemid 44414560)
8. Bate C, Tayebi M, Diomede L, Salmona M and Williams A: Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One 4: e8221, 2009.
9. Gu Y, Fujioka H, Mishra RS, Li R and Singh N: Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 277: 2275-2286, 2002. (Pubitemid 34968815)
10. La Mendola D, Pietropaolo A, Pappalardo G, Zannoni C and Rizzarelli E: Prion proteins leading to neurodegeneration. Curr Alzheimer Res 5: 579-590, 2008.
11. Singh N, Gu Y, Bose S, Kalepu S, Mishra RS and Verghese S: Prion peptide 106-126 as a model for prion replication and neurotoxicity. Front Biosci 7: a60-a71, 2002.
12. Brown DR: PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochem J 352: 511-518, 2000.
13. Forloni G, Bugiani O, Tagliavini F and Salmona M: Apoptosis-mediated neurotoxicity induced by beta-amyloid and PrP fragments. Mol Chem Neuropathol 28: 163-171, 1996. (Pubitemid 26275064)
14. Didonna A and Legname G: Aberrant ERK 1/2 complex activation and localization in scrapie-infected GT1-1 cells. Mol Neurodegener 5: 29, 2010.
15. Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S and Kellermann O: NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 100: 13326-13331, 2003. (Pubitemid 37444741)
16. Jeong JK, Seol JW, Moon MH, et al: Cellular cholesterol enrichment prevents prion peptide-induced neuron cell damages. Biochem Biophys Res Commun 401: 516-520, 2010.
17. Vane JR and Botting RM: Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47 (Suppl. 2): S78-S87, 1998. (Pubitemid 28493273)
18. Yang L, Zhou X, Yang J, Yin X, Han L and Zhao D: Aspirin inhibits cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with microglia activation in vitro. J Neuroimmunol 199: 10-17, 2008.
19. Blanco A, Alvarez S, Fresno M and Munoz-Fernandez MA: Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κB dependent manner. J Alzheimers Dis 22: 493-505, 2010.
20. Gao F, Bales KR, Dodel RC, et al: NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line. Brain Res Mol Brain Res 105: 108-114, 2002. (Pubitemid 35245617)
21. Pan MR, Chang HC and Hung WC: Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 20: 1134-1141, 2008.
22. Seo JS, Seol JW, Moon MH, Jeong JK, Lee YJ and Park SY: Hypoxia protects neuronal cells from human prion protein fragment-induced apoptosis. J Neurochem 112: 715-722, 2010.
23. Forloni G, Angeretti N, Chiesa R, et al: Neurotoxicity of a prion protein fragment. Nature 362: 543-546, 1993. (Pubitemid 23113029)
24. Minghetti L and Pocchiari M: Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases. Int Rev Neurobiol 82: 265-275, 2007.
25. Bate C, Tayebi M, Diomede L, Salmona M and Williams A: Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol 6: 39, 2008.
26. Eliopoulos AG, Dumitru CD, Wang CC, Cho J and Tsichlis PN: Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J 21: 4831-4840, 2002.
27. Faour WH, He Q, Mancini A, Jovanovic D, Antoniou J and Di Battista JA: Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-κB-mediated MEKK1-induced MMP-1 expression. J Biol Chem 281: 19849-19860, 2006. (Pubitemid 44081199)
28. Bate C, Rutherford S, Gravenor M, Reid S and Williams A: Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport 13: 1933-1938, 2002.